DBV TECHNOLOGIE/S (DBVT) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a hold rating to a sell rating in a research note released on Wednesday morning.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

A number of other equities analysts also recently weighed in on DBVT. BidaskClub raised shares of DBV TECHNOLOGIE/S from a sell rating to a hold rating in a research note on Tuesday, August 14th. Bank of America lowered their target price on shares of DBV TECHNOLOGIE/S from $33.00 to $30.00 and set a buy rating for the company in a research note on Friday, November 2nd. Morgan Stanley lifted their target price on shares of DBV TECHNOLOGIE/S from $27.00 to $28.00 and gave the stock an equal weight rating in a research note on Friday, July 13th. Finally, ValuEngine raised shares of DBV TECHNOLOGIE/S from a sell rating to a hold rating in a research note on Thursday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company. DBV TECHNOLOGIE/S has a consensus rating of Buy and an average price target of $33.67.

Shares of DBVT stock traded down $0.80 during trading hours on Wednesday, hitting $19.20. 97,222 shares of the company’s stock traded hands, compared to its average volume of 120,120. The company has a market capitalization of $1.14 billion, a P/E ratio of -5.70 and a beta of 1.23. DBV TECHNOLOGIE/S has a 12 month low of $16.65 and a 12 month high of $26.98.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC raised its stake in DBV TECHNOLOGIE/S by 6.0% during the second quarter. Janus Henderson Group PLC now owns 3,022,888 shares of the company’s stock worth $58,312,000 after buying an additional 169,765 shares during the last quarter. Jennison Associates LLC raised its stake in DBV TECHNOLOGIE/S by 1.4% during the third quarter. Jennison Associates LLC now owns 1,731,291 shares of the company’s stock worth $38,885,000 after buying an additional 23,559 shares during the last quarter. FMR LLC raised its stake in DBV TECHNOLOGIE/S by 1.4% during the third quarter. FMR LLC now owns 1,325,676 shares of the company’s stock worth $29,775,000 after buying an additional 18,744 shares during the last quarter. Boxer Capital LLC raised its stake in DBV TECHNOLOGIE/S by 4.4% during the second quarter. Boxer Capital LLC now owns 1,065,000 shares of the company’s stock worth $20,544,000 after buying an additional 45,000 shares during the last quarter. Finally, VHCP Management II LLC bought a new position in DBV TECHNOLOGIE/S during the second quarter worth $12,029,000. 44.65% of the stock is owned by institutional investors and hedge funds.

About DBV TECHNOLOGIE/S

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Recommended Story: What is the yield curve?

Get a free copy of the Zacks research report on DBV TECHNOLOGIE/S (DBVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply